Kura Oncology Reports Third Quarter 2026 Financial Results

Kura Oncology reported 53% sequential revenue growth for its FDA-approved menin inhibitor, KOMZIFTI, in the third quarter of 2026. New patient starts for the therapy rose 30%, and the company said it retained a majority share of new starts in its target market. Kura also provided updates on its ongoing clinical development and commercial priorities; the report did not specify total revenue, profit, or stock-price movements.